Aimisen specializes in the development, registration, production, sales, and testing of global non-invasive screening products for malignant tumors.
Missing: Aimisen's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Aimisen's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Aimisen
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Aimisen is included in 3 Expert Collections, including Cancer.
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Aimisen Web Traffic
Aimisen Frequently Asked Questions (FAQ)
When was Aimisen founded?
Aimisen was founded in 2015.
Where is Aimisen's headquarters?
Aimisen's headquarters is located at Building B10, Hi-Tech Medical Equipment Park, No. 818 Gaoxin Avenue, East Lake High-tech Development Zone, Wuhan.
What is Aimisen's latest funding round?
Aimisen's latest funding round is Series C.
How much did Aimisen raise?
Aimisen raised a total of $17.46M.
Who are the investors of Aimisen?
Investors of Aimisen include CCB International, Wuhan Hi-Tech, Sanya Xuanpan, Hybribio Biotech, Changjiang Securities and 5 more.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.